Octavus Consulting- Evidence-Based Consulting Services.

Call us: +91 120 428 0707

Email us: bd@octavusconsulting.com

Contact Us
Contact Us

Obesity Deep Dive 2025: Latest Pharma Trends, Breakthroughs & Market Insights

Insights Details

Month: Nov 25

Tags: Obesity, Conference, Pre-clinical, Phase 1, Phase 2, Phase 3, US FDA, EMA, Company Profile, Product profile, Deal Analysis, Funding Analysis, Landscape, Global Market Size, Clinical trials, Milestones, Catalyst, GENETICS, Market trends, Obesity Week

Let’s Work Together for Development

Call us directly, submit a sample or email us!

Business Address
First Floor, B-66, Sector 63,
Noida, UP, India-201301
Connect With Us
Call us: +91 120 428 0707
bd@octavusconsulting.com
Working Hours
Mon - Fri: 10.00 AM - 07.00 PM
Holidays : Closed
Get in Touch With Us

About topic:

This insight corner explains, Why obesity is now seen as a fast‑growing, multi‑billion‑dollar chronic disease market, dominated by GLP‑1–based drugs but rapidly expanding into more mechanisms, more players, and broader digital/adjacent offerings

Obesity Deep Dive 2025: Latest Pharma Trends, Breakthroughs & Market Insights

Highlights:

Obesity is a non-exhaustive market with enormous patient populations and multiple comorbidities (NASH/MASH, sleep apnea, heart failure, CV disease), allowing large, mid-size, and emerging players to compete across drugs, devices, and services without any single player dominating
Over 150 obesity drugs are in development with 100+ phase 3 programs; R&D is rapidly shifting from single GLP-1 agonists to dual/triple incretin combinations and non-GLP-1 targets (MC4R, RNA) aimed at superior weight loss, tolerability, and cardiometabolic outcomes
Numerous phase 2/3 readouts for multi-agonists and next-gen agents are expected through 2026, poised to reshape clinical efficacy benchmarks and market shares, with trials increasingly targeting cardiometabolic endpoints rather than weight alone to broaden clinical and reimbursable indications
Big pharma’s are aggressively licensing and acquiring next-wave incretin and non-incretin assets, while early-stage biotech’s differentiate on novel mechanisms, oral formulations, and less-frequent dosing—setting up highly competitive dynamic through 2026

    Download Insights Presentation
    Download Pdf
    PREVIOUS PROJECT